Today's Rundown GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working? Private equity firms Hellman & Friedman, Bain Capital to buy Athenahealth in $17B deal Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data Humana reaches value-based care deal with Minnesota-based Allina Health Pear's digital therapeutic for alcohol use disorder bears fruit with FDA breakthrough tag Sagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitch Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets It's a wrap: Merck collects enough Acceleron shares for $11.5B buyout despite activist investor defiance BD upsizes San Diego presence with new 220K-square-foot biosciences R&D facility Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal UK launches review of racial, gender biases in medical devices, sparked by disproportionate COVID deaths FDA unlocks faster clearances for future hepatitis C diagnostics Digital MSK provider Sword Health gets $189M, boosts valuation to $1.8B Featured Story | By Ben Adams GlaxoSmithKline is making its first major foray into treating the fatty liver condition known as NASH as it pens a $1 billion asset pact with Arrowhead Pharmaceuticals. read more |
| |
|---|
|
Top Stories By Natalie Missakian Pharma companies vying for a piece of the lucrative migraine market have gone all-in on marketing, turning to Olympic athletes and Hollywood stars to pitch recently approved brands in TV commercials and on social media. But is the message sinking in with patients? Apparently not yet, a new survey from Phreesia Life Sciences suggests. read more By Heather Landi Private equity firms Bain Capital and Hellman & Friedman LLC plan to buy Athenahealth for $17 billion, marking the second time in less than three years the health tech company has changed ownership. read more By Nick Paul Taylor The poster child of the Spanish biotech scene has secured its exit. Having twice smashed the Spanish biotech financing record in recent years, Sanifit has now accepted a 205 million euro ($231 million) buyout bid from Vifor Pharma. read more By Robert King Humana announced a value-based care deal with Minnesota health system Allina Health, the latest agreement it made since becoming a direct contracting entity. read more By Andrea Park With its proposed SPAC deal only days away from shareholder approval, Pear Therapeutics is already plotting out its future as a publicly traded company. read more By Fraiser Kansteiner Sagent Pharmaceuticals is recalling four lots of injectable levetiracetam, which is used to treat certain types of seizures, thanks to a "lack of container closure integrity" seen in sample vials on reserve. The drug could become unsterile if the container it's stored in doesn't seal properly, Sagent explained in a recall announcement posted by the FDA. read more By Ben Adams Neurocrine Biosciences and Sosei Heptares, no strangers to major research pacts, are joining forces for a range of early- to midstage neuro assets. read more By Angus Liu Merck & Co. has consumed Acceleron Pharma. Notwithstanding clamorous activist investors, the company has collected enough Acceleron shares to complete the transaction. read more By Andrea Park BD’s life sciences footprint is about to get quite a bit bigger—220,000 square feet bigger, to be exact. read more By Nick Paul Taylor Xencor has finally found a buyer for its autoimmune disease bispecific antibody obexelimab. Almost three years after deciding to partner the drug in the wake of a failed phase 2, Xencor has offloaded the asset to Zenas BioPharma in a backloaded deal worth up to $480 million. read more By Andrea Park Racial and gender biases in medical devices are "totally unacceptable," said Sajid Javid, the U.K.’s secretary of state for health and social care. read more By Conor Hale The FDA has eased up on makers of new diagnostic tests for hepatitis C, granting them a quicker pathway to the market. The reclassification allows diagnostic developers to seek 510(k) clearances instead of completing full premarket approval applications. read more By Rebecca Torrence Virtual MSK provider Sword Health has hit unicorn status with an additional $189 million raised, catapulting its valuation to $1.8 billion. The company has raised nearly $300 million this year alone. read more |
| Webinar: Give Your Medtech Sales a Collaboration Advantage Tuesday, November 30 | 12pm ET / 9am PT Medtech companies have long been burdened by inefficient communication between front office (sales) and back office (operations). It’s clear a new approach is needed – one that increases collaboration and communication between sales and operations, improves the customer experience, and increases revenue. Learn More. |
|
